

CURRICULUM VITAE

Dae Young Zang, MD, PhD

CURRENT POSITION/ AFFILIATION:

Chief, Division of Hematology and Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, South Korea

Chairman and Professor, Division of Hematology-Oncology, Hallym University College of Medicine, South Korea

DATE OF BIRTH:

Feb. 16, 1963

PROFESSIONAL EDUCATION:

1981-1982 General Division, Sungkwunguan University, South Korea

1982-1989 MD, College of Medicine, Hallym University, South Korea

1993-1995 MS, Internal Medicine, Graduate School, Hallym University, Korea

1995-1998 PhD, Internal Medicine, Hallym University, South Korea

POSTGRADUATE PROFESSIONAL TRAINING AND AFFILIATION:

1995-1998 Clinical and Research Fellowship, Division of Hematology and Oncology
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine
South Korea

1998-2000 Clinical Research Instructor/ Research Associate, Clinical Research Division
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA

PROFESSIONAL SOCIETIES:

Member, American Society of Oncology

Member, American Society of Hematology

Member, European Society of Medical Oncology

Member, Korean Society of Hematopoietic Stem Cell Transplantation

Executive secretary, Korean Association of Clinical Oncology

RESEARCH FIELDS AND INTERESTS

1. Gastrointestinal cancer: Phase I, II, and III clinical trials using novel combination chemotherapeutic regimens for gastric, colorectal, pancreas, and biliary cancers.

2. Myelodysplastic syndrome and apoptosis: One focus of our research is the characterization of the underlying mechanisms with the goal of developing novel strategies to recover normal hematopoiesis by selective killing of clonal cells.

REPRESENTATIVE PUBLICATIONS (Total publications: 197)

1. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ, Jang KM. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. *Ann Oncol* [Epub] doi:10.1093/annonc/mdn721, 2009

2. Zang D, Yang D, Kim M, Jang K, Hwang S, Yoo K, Han T, Kim H, Kim H, Kwon J, Song H, Park S, Jung J, Kim H, Kim J. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. *Cancer Chemother Pharmacol* [Epub] doi:10.1007/s00280-009-0936-6, 2009

3. Zang DY, Deeg HJ. Allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. *Curr Opin Hematol* 2009 pending

4. Zang D, Yang D, Lee H, Hwang S, Song H, Jung J, Kwon J, Kim H, Kim J, Park S, Park, Kim M, Jang K, Park C, Kim J, Lee B. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with considering to age. *Cancer Chemother Pharmacol*, 63:509-516, 2009
5. Lee J, Kang Y, Kang H, Lee K, Zang D, Ryoo B, Kim J, Park S, Kang W, Shin D, Chang H, Kim T, Baek J, Min Y. A randomized multi-center phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. *Br J Cancer*, 99:584-590, 2008
6. Lee KH, Kim MK, Kim YH, Ryoo BY, Lim HY, Song HS, Kim HK, Lee MA, Im SA, Chang HM, Cho JY, Zang DY, Kim BS, Kim JS. Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. *Cancer Chemother Pharmacol* [Epub] doi:10.1007/s00280-008-0873-9, 2008
7. Lee J, Min Y, Chung C, Kim B, Yoon H, Jo D, Shin H, Bang S, Won J, Zang D, Kim H, Chi H, Lee K, Cheong J, Kim J, Kim S, Park S, Park S, Chung J, Lee J, Park C; Korea Society of Hematology AML/MDS Working Party. Prognostic implications of the immunophenotype in biphenotypic acute leukemia. *Leukemia Lymphoma* 49:700-709, 2008
8. Zang D. A new option for advanced gastric cancer- docetaxel and novel oral fluoropyrimidine combination chemotherapy. *J Kor Med Assoc* 50:556-560, 2007
9. Zang D. Updates in post-operative chemotherapy for gastric cancer. *J Clin Cancer Res* 1:58-63, 2007
10. Zang D. Second-line chemotherapy in advanced gastric cancer. *Kor Clin Oncol* 2:91-97, 2006
11. Zang D, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on vitro hemopoiesis. *Blood* 98:3058-3065, 2001
12. Zang D, Deeg H,J, Gooley T, Anderson JE, Anasetti C, Sanders J, Myerson D, Storb R, Appelbaum F. Treatment of chronic myelomonocytic leukemia by allogeneic transplantation. *Br J Haematol* 110:217-222, 2000